Cargando…
Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia
PURPOSE: In this study, we examined the effects of dapagliflozin on changes in hematopoiesis, iron metabolism, and body composition indices in elderly type 2 diabetic patients with renal impairment and investigated the potential of dapagliflozin to treat renal anemia. PATIENTS AND METHODS: The parti...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290476/ https://www.ncbi.nlm.nih.gov/pubmed/37363130 http://dx.doi.org/10.2147/DMSO.S411504 |
_version_ | 1785062505963323392 |
---|---|
author | Osonoi, Takeshi Shirabe, Shinichiro Saito, Miyoko Hosoya, Mitsuru Watahiki, Norie Douguchi, Satako Ofuchi, Kensuke Katoh, Makoto |
author_facet | Osonoi, Takeshi Shirabe, Shinichiro Saito, Miyoko Hosoya, Mitsuru Watahiki, Norie Douguchi, Satako Ofuchi, Kensuke Katoh, Makoto |
author_sort | Osonoi, Takeshi |
collection | PubMed |
description | PURPOSE: In this study, we examined the effects of dapagliflozin on changes in hematopoiesis, iron metabolism, and body composition indices in elderly type 2 diabetic patients with renal impairment and investigated the potential of dapagliflozin to treat renal anemia. PATIENTS AND METHODS: The participants were elderly type 2 diabetics with renal impairment, and the indices of diabetes management, hematopoiesis, iron metabolism, and body composition were compared before and after dapagliflozin treatment. RESULTS: Fourteen subjects were given dapagliflozin 5 mg once daily for 12 weeks, three of whom had eligibility criteria deviations, such as serum ferritin <50 ng/mL. For this purpose, 14 subjects were analyzed as full analysis set (FAS) and 11 as per-protocol set (PPS). FAS analysis revealed that dapagliflozin had no effect on hemoglobin A1c after 12 weeks but significantly decreased body mass index, significantly increased hemoglobin, hematocrit, and red blood cell count, significantly decreased log ferritin level only of iron metabolism index, and no important change in body water content. PPS analysis, on the other hand, revealed that dapagliflozin 12-week treatment showed a significant decrease in log hepcidin, serum iron, and transferrin saturation. CONCLUSION: These findings suggest that a 12-week course of dapagliflozin causes an increase in hemoglobin levels due to its hematopoietic effects in elderly type 2 diabetics with renal impairment, but that these effects may be independent of body water loss and iron metabolism improvement. |
format | Online Article Text |
id | pubmed-10290476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-102904762023-06-25 Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia Osonoi, Takeshi Shirabe, Shinichiro Saito, Miyoko Hosoya, Mitsuru Watahiki, Norie Douguchi, Satako Ofuchi, Kensuke Katoh, Makoto Diabetes Metab Syndr Obes Original Research PURPOSE: In this study, we examined the effects of dapagliflozin on changes in hematopoiesis, iron metabolism, and body composition indices in elderly type 2 diabetic patients with renal impairment and investigated the potential of dapagliflozin to treat renal anemia. PATIENTS AND METHODS: The participants were elderly type 2 diabetics with renal impairment, and the indices of diabetes management, hematopoiesis, iron metabolism, and body composition were compared before and after dapagliflozin treatment. RESULTS: Fourteen subjects were given dapagliflozin 5 mg once daily for 12 weeks, three of whom had eligibility criteria deviations, such as serum ferritin <50 ng/mL. For this purpose, 14 subjects were analyzed as full analysis set (FAS) and 11 as per-protocol set (PPS). FAS analysis revealed that dapagliflozin had no effect on hemoglobin A1c after 12 weeks but significantly decreased body mass index, significantly increased hemoglobin, hematocrit, and red blood cell count, significantly decreased log ferritin level only of iron metabolism index, and no important change in body water content. PPS analysis, on the other hand, revealed that dapagliflozin 12-week treatment showed a significant decrease in log hepcidin, serum iron, and transferrin saturation. CONCLUSION: These findings suggest that a 12-week course of dapagliflozin causes an increase in hemoglobin levels due to its hematopoietic effects in elderly type 2 diabetics with renal impairment, but that these effects may be independent of body water loss and iron metabolism improvement. Dove 2023-06-20 /pmc/articles/PMC10290476/ /pubmed/37363130 http://dx.doi.org/10.2147/DMSO.S411504 Text en © 2023 Osonoi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Osonoi, Takeshi Shirabe, Shinichiro Saito, Miyoko Hosoya, Mitsuru Watahiki, Norie Douguchi, Satako Ofuchi, Kensuke Katoh, Makoto Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia |
title | Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia |
title_full | Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia |
title_fullStr | Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia |
title_full_unstemmed | Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia |
title_short | Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia |
title_sort | dapagliflozin improves erythropoiesis and iron metabolism in type 2 diabetic patients with renal anemia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290476/ https://www.ncbi.nlm.nih.gov/pubmed/37363130 http://dx.doi.org/10.2147/DMSO.S411504 |
work_keys_str_mv | AT osonoitakeshi dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia AT shirabeshinichiro dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia AT saitomiyoko dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia AT hosoyamitsuru dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia AT watahikinorie dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia AT douguchisatako dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia AT ofuchikensuke dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia AT katohmakoto dapagliflozinimproveserythropoiesisandironmetabolismintype2diabeticpatientswithrenalanemia |